DIY Extinction: How CRISPR Gene Editing CouldThreaten Biodiversity
What is CRISPR and why are scientists worried about it?
CRISPR is a powerful gene-editing technology that allows scientists to precisely alter DNA.
While it promises breakthroughs in medicine and agriculture, its growing accessibility—including DIY CRISPR kits—has raised concerns among biosecurity experts about potential risks to ecosystems and global health.
CRISPR is one of the most powerful biological tools ever created: a gene-editing technology that allows scientists to alter DNA with unprecedented precision. Its promise is enormous. Researchers are using CRISPR to engineer crops that resist disease, improve nutritional value, and survive harsh climates. In medicine, the technology is opening the door to therapies for genetic disorders that were once considered untreatable. As gene editing moves from experimental research into clinical trials and commercial biotechnology, CRISPR is increasingly viewed not only as a scientific breakthrough but as a foundational platform technology in genomics and biotechnology.
But CRISPR’s accessibility is part of what makes it unsettling. Unlike earlier generations of biotechnology that required specialized facilities, CRISPR is relatively cheap, portable, and increasingly available outside traditional laboratories. The same tool that can repair genes can also be misused.
A widely cited example is biohacker Josiah Zayner, founder of The ODIN, a company that sells DIY CRISPR kits to hobbyists. In 2017, Zayner publicly injected himself with an experimental CRISPR construct, claiming it could increase muscle growth. While the stunt was more symbolic than scientifically effective, it illustrated a deeper concern: powerful gene-editing tools are migrating into spaces with little oversight. Self-experimention may primarily endanger the individual, but it signals a cultural shift in how casually we treat technologies capable of permanently altering biology.
The greater risk is not a single reckless experiment, but the normalization of biological engineering without robust safeguards. As gene-editing techniques advance, so does the theoretical possibility of modifying viruses. Today, such work is tightly regulated in professional research environments. However, the barriers to entry are falling. A future in which malicious actors attempt to engineer pathogens that spread more efficiently or evade existing treatments is no longer pure fiction—it is a scenario biosecurity researchers and national security analysts increasingly study.
COVID-19 demonstrated how profoundly a virus can disrupt global systems. A deliberately engineered pathogen designed to maximize transmissibility or immune escape could, in principle, be far more destructive. CRISPR is celebrated for its precision in agriculture and medicine, but that same precision could be repurposed toward harm. The technology itself is neutral; its consequences depend entirely on the social, ethical, and regulatory frameworks surrounding it.
Beyond human health, the spread of gene-editing tools also raises questions for biodiversity and ecosystems. Technologies such as gene drives—genetic systems designed to spread engineered traits through entire populations—demonstrate how gene editing could reshape species and ecological systems. While researchers are exploring such tools to control disease-carrying mosquitoes or invasive species, they also illustrate how profoundly biotechnology could alter natural systems if deployed irresponsibly.
Most concerning is not the technology's power, but the widening gap between capability and oversight. Professional laboratories operate under stringent biosafety protocols and ethical review boards. DIY spaces rarely do. This creates an asymmetry in which defensive research moves slowly through regulated channels, while potential threats could emerge from ungoverned environments.
This tension between innovation and oversight is likely to shape the future of the biotechnology industry. As CRISPR and related gene-editing technologies become foundational tools in medicine, agriculture, and synthetic biology, governments and international institutions will face increasing pressure to develop governance frameworks capable of managing both opportunity and risk. The regulatory environment surrounding gene editing may ultimately become one of the most important variables shaping how biotechnology companies develop and deploy these tools.
The question is not whether we should stop developing gene-editing tools—their benefits are too significant to ignore. The real challenge is ensuring that our governance, public understanding, and safety culture evolve as quickly as the technology. Without that balance, the democratization of biotechnology risks outpacing our ability to control it. We need investment in pathogen surveillance systems, international agreements on biological research standards, and perhaps most critically, a broader public literacy about both the promise and the responsibility that comes with rewriting the code of life.
As biotechnology becomes increasingly decentralized, the governance of gene-editing tools may become as important to global stability as the technologies themselves. The future of CRISPR depends less on the technology itself than on our collective wisdom in managing it. That may be the most unsettling realization of all.
